A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01311050

Enrollment

Registered

2011-03-09

Start date

2009-01-31

Completion date

Unknown

Last updated

2011-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal Cancer

Keywords

Metastatic Colorectal Cancer

Brief summary

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Detailed description

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Interventions

DRUGCapecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

14 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients with diagnosed Metastatic Colorectal Cancer

Exclusion criteria

* Patients with diagnosis other than Metastatic Colorectal Cancer

Countries

Saudi Arabia

Contacts

Primary ContactShouki Bazarbashi, M.D.

+966-1-4423949

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026